PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.

Bibliografski detalji
Glavni autori:	Cooper, C, Liggins, A, Ait-Tahar, K, Roncador, G, Banham, A, Pulford, K
Format:	Journal article
Jezik:	English
Izdano:	2006

Slični predmeti

Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
od: Campbell, A, i dr.
Izdano: (2010)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
od: Ait-Tahar, K, i dr.
Izdano: (2009)

PASD1 is a potential multiple myeloma-associated antigen.
od: Sahota, S, i dr.
Izdano: (2006)

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
od: Joseph-Pietras, D, i dr.
Izdano: (2010)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
od: Ait-Tahar, K, i dr.
Izdano: (2009)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
od: Ait-Tahar, K, i dr.
Izdano: (2011)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
od: Kamel Ait-Tahar, i dr.
Izdano: (2011-01-01)

A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
od: Liggins, A, i dr.
Izdano: (2004)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
od: Liggins, A, i dr.
Izdano: (2004)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
od: Cooper, C, i dr.
Izdano: (2011)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
od: Liggins, A, i dr.
Izdano: (2010)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
od: Liggins, A, i dr.
Izdano: (2010)

Erratum: Serologic detection of diffuse large B-cell lymphoma-associated antigens (International Journal of Cancer (2004) 110 (563-569))
od: Liggins, A, i dr.
Izdano: (2004)

Identification of lymphoma-associated antigens using SEREX.
od: Liggins, A, i dr.
Izdano: (2005)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
od: Christopher D O Cooper, i dr.
Izdano: (2011-01-01)

Immunochemical studies of antigenic lymphoma-associated proteins.
od: Pulford, K, i dr.
Izdano: (2002)

CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY
od: D. I. Vodolazhsky, i dr.
Izdano: (2017-06-01)

Cancer testis antigen and immunotherapy
od: Krishnadas DK, i dr.
Izdano: (2013-04-01)

MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
od: Liggins, A, i dr.
Izdano: (2007)

Sp17 protein expression and major histocompatibility class I and II epitope presentation in diffuse large B cell lymphoma patients
od: Ait-Tahar, K, i dr.
Izdano: (2017)

Cancer Testis Antigens and Immunotherapy: A new Dawn
od: Zhang Bingcan
Izdano: (2021-01-01)

Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.
od: Lawrie, C, i dr.
Izdano: (2006)

Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling
od: Wong, K, i dr.
Izdano: (2008)

Identification of Huntingtin interacting protein 1 related (HIP1R) as a novel lymphoma autoantigen using antigen array profiling
od: Wong, K, i dr.
Izdano: (2009)

Unveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma
od: Shenghua Zhuo, i dr.
Izdano: (2024-10-01)

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.
od: Barrans, S, i dr.
Izdano: (2004)

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers
od: Huihan Ai, i dr.
Izdano: (2023-06-01)

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects
od: Xiao Wei, i dr.
Izdano: (2019-05-01)

Expression of cancer testis antigens in patients with Hodgkin's lymphoma and their clinical correlation
od: L.M. Hodgson Reyes, i dr.
Izdano: (2018-01-01)

RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis.
od: Patel, S, i dr.
Izdano: (2012)

RNASET2 - An autoantigen in anaplastic large cell lymphoma identified by protein array analysis
od: Patel, S, i dr.
Izdano: (2012)

Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
od: Brown, P, i dr.
Izdano: (2008)

Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse—a case report
od: M. C. Suresh Babu, i dr.
Izdano: (2020-05-01)

Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.
od: Patel, S, i dr.
Izdano: (2014)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
od: Madiha Iqbal, i dr.
Izdano: (2022-01-01)

The potential value of cancer‐testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy
od: Lina Lin, i dr.
Izdano: (2024-06-01)

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients
od: Kamel Ait-Tahar, i dr.
Izdano: (2017-01-01)

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
od: Lawrie, C, i dr.
Izdano: (2008)

LYMPHOMA PADA TESTIS
od: Dian Yuliartha Lestari, i dr.
Izdano: (2018-09-01)

Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
od: Griffiths, R, i dr.
Izdano: (2010)